New Mesothelioma Test Improves Diagnostic Accuracy
A new diagnostic tool helps clinicians accurately identify mesothelioma while preserving biopsy tissue for patients.
Updated on Oct. 28, 2026 in Cancer
Live Poll
Do you believe new diagnostic technologies provide significant benefits for long-term cancer patient survival?
Roche has launched the VENTANA BAP1 (SP527) immunohistochemistry test to help clinicians distinguish malignant mesothelioma from other cancers. This diagnostic tool provides a faster way to identify specific malignancy markers, aiding patients currently undergoing tissue analysis for complex diagnoses.
Why it matters
Accurate differential diagnosis is vital for mesothelioma, which has a median survival of only 12 to 18 months, because it ensures patients receive the correct treatment pathway early. This test helps preserve limited biopsy tissue by combining BAP1 detection with other essential assays.
The assay is registered as a Class I IVD with the FDA and received Class C approval under IVDR for its ability to detect nuclear loss of BAP1 expression, a highly specific marker for mesothelioma. It remains unknown how quickly this technology will be integrated into routine diagnostic workflows.
The players
Roche
A global healthcare leader specializing in pharmaceuticals and automated diagnostics for cancer and other complex diseases.
The details
The test utilizes automated immunohistochemistry to identify the loss of nuclear BAP1 protein expression, which specifically indicates malignant mesothelial proliferation. By pairing this analysis with MTAP and Claudin-4 assays, pathologists can reach a diagnosis using a single tissue sample, preventing the tissue exhaustion common in traditional testing methods. This process is critical for differentiating mesothelioma from other conditions like lung or breast cancers that may appear similar under basic examination.
Timeline
October 28, 2026: Roche announced the global launch of the BAP1 test.
Health Landscape
This launch fits into the broader evolution of precision pathology, where automated systems are increasingly used to streamline the diagnosis of rare cancers. It builds on the current clinical reliance on VENTANA immunohistochemistry automated testing systems to maximize diagnostic output.
For patients undergoing biopsy for suspected mesothelioma, this test can provide clearer results while minimizing the need for repeat procedures. If you or a loved one are navigating a complex lung or mesothelial diagnosis, it is worth discussing the availability of specific immunohistochemistry markers with your oncology team.
The takeaway
Reliable diagnosis of mesothelioma is critical given the disease's limited median survival time of 12 to 18 months. Patients should ask their pathologist or oncologist if advanced immunohistochemistry testing is being used to confirm their diagnosis and protect tissue integrity.
Further reading
Learn more about the latest innovations in Cancer diagnostics and management.
More information
For more information on the diagnostic test, visit the Roche official company website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe new diagnostic technologies provide significant benefits for long-term cancer patient survival?
